The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Open accessAbstract
Both genome-wide genetic and epigenetic alterations are fundamentally important for the development of cancers, but the interdependence of these aberrations is poorly understood. Glioblastomas and other cancers with the CpG island methylator phenotype (CIMP) constitute a subset of tumours with extensive epigenomic aberrations and a distinct biology. Glioma CIMP (G-CIMP) is a powerful determinant of tumour pathogenicity, but the molecular basis of G-CIMP remains unresolved. Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by remodelling the methylome. This remodelling results in reorganization of the methylome and transcriptome. Examination of the epigenome of a large set of intermediate-grade gliomas demonstrates a distinct G-CIMP phenotype that is highly dependent on the presence of IDH mutation. Introduction of mutant IDH1 into primary human astrocytes alters specific histone marks, induces extensive DNA hypermethylation, and reshapes the methylome in a fashion that mirrors the changes observed in G-CIMP-positive lower-grade gliomas. Furthermore, the epigenomic alterations resulting from mutant IDH1 activate key gene expression programs, characterize G-CIMP-positive proneural glioblastomas but not other glioblastomas, and are predictive of improved survival. Our findings demonstrate that IDH mutation is the molecular basis of CIMP in gliomas, provide a framework for understanding oncogenesis in these gliomas, and highlight the interplay between genomic and epigenomic changes in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“IDH mutant gliomas thus manifest a CpG island methylator phenotype (G-CIMP)10,11, though the functional significance of this altered epigenetic state remains unclear.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [11]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Turcan et al., 2012
In the citing paper
“Specifically, owing to the interference with TET family proteins, the mutation causes the CpG island methylator phenotype116,123.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [123]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Turcan et al., 2012
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [82]
In the citing paper
“Like TH17 cells, CD8+ T cells are highly dependent on the activation of HIF-1α and glycolysis, which is responsible for mediating trafficking into hypoxic tumour environments and inflamed tissue147,148.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationConsed: a graphical tool for sequence finishing.Preprint
Gordon, D., Abajian, C., & Green, P. (1998) · Genome Research · doi:10.1101/gr.8.3.195 · Cited by 3,706
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,164
Flagged first, then by citations
2 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 1,002
Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments
Merz, F., Gaunitz, F., Dehghani, F., Renner, C., Meixensberger, J., Gutenberg, A., Giese, A., Schopow, K., Hellwig, C. T., Schäfer, M., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not003 · Cited by 123
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
Pellegatta, S., Valletta, L., Corbetta, C., Patanè, M., Zucca, I., Sirtori, F. R., Bruzzone, M. G., Fogliatto, G., Isacchi, A., Pollo, B., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0180-0 · Cited by 123
Chaturvedi, A., Herbst, L., Pusch, S., Klett, L. C., Goparaju, R., Stichel, D., Kaulfuß, S., Panknin, O., Zimmermann, K. C., Toschi, L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.46 · Cited by 125
Proteomic and phosphoproteomic landscapes of acute myeloid leukemia
Kramer, M. H., Zhang, Q., Sprung, R. W., Day, R. B., Erdmann-Gilmore, P., Li, Y., Xu, Z., Helton, N., George, D. R., Mi, Y., et al. (2022) · Blood · doi:10.1182/blood.2022016033 · Cited by 124
Wang, L. M., Englander, Z. K., Miller, M. L., & Bruce, J. N. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-23705-8_1 · Cited by 133
van den Bent, M. J., Erdem‐Eraslan, L., Idbaïh, A., de Rooi, J., Eilers, P. H. C., Spliet, W. G. M., den Dunnen, W. F. A., Tijssen, C. C., Wesseling, P., Smitt, P. A. E. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1157 · Cited by 120
Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
Miranda‐Gonçalves, V., Lameirinhas, A., Henrique, R., & Jerónimo, C. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00427 · Cited by 125
Pediatric Brain Tumor Genetics: What Radiologists Need to Know
AlRayahi, J., Zápotocký, M., Ramaswamy, V., Hanagandi, P. B., Branson, H. M., Mubarak, W. M., Raybaud, C., & Laughlin, S. (2018) · Radiographics · doi:10.1148/rg.2018180109 · Cited by 125
Grassian, A. R., Lin, F., Barrett, R., Liu, Y., Jiang, W., Korpal, M., Astley, H. M., Gitterman, D. P., Henley, T., Howes, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417832 · Cited by 122
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation
Ohka, F., Ito, M., Ranjit, M., Senga, T., Motomura, A., Motomura, K., Saito, K., Kato, K., Kato, Y., Wakabayashi, T., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-1784-5 · Cited by 124
Reprogramming the epigenome with vitamin C
Lee Chong, T., Ahearn, E. L., & Cimmino, L. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00128 · Cited by 120
AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis
Li, N., Xue, W., Yuan, H., Dong, B., Ding, Y., Liu, Y., Jiang, M., Kan, S., Sun, T., Ren, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91144 · Cited by 119
Non-invasive metabolic imaging of brain tumours in the era of precision medicine
Kim, M. M., Parolia, A., Dunphy, M. P., & Venneti, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.108 · Cited by 121
Epigenetic Targeting of Glioblastoma
Romani, M., Pistillo, M. P., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00448 · Cited by 119
Li, Y., Xu, J., Chen, H., Bai, J., Li, S., Zhao, Z., Shao, T., Jiang, T., Ren, H., Kang, C., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1054 · Cited by 116
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
Karpel‐Massler, G., Ishida, C. T., Bianchetti, E., Zhang, Y., Shu, C., Tsujiuchi, T., Banu, M. A., Garcia, F., Roth, K. A., Bruce, J. N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00984-9 · Cited by 121
Modrek, A. S., Golub, D., Khan, T. A., Bready, D., Prado, J., Bowman, C., Deng, J., Zhang, G., Rocha, P. P., Raviram, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.009 · Cited by 118
Gao, L., Wang, K., Zhou, Y., Fang, J., Qin, X., & Du, G. (2018) · Scientific Reports · doi:10.1038/s41598-017-18325-7 · Cited by 117
The role of 5-hydroxymethylcytosine in human cancer
Pfeifer, G. P., Xiong, W., Hahn, M. A., & Jin, S. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1896-7 · Cited by 118
Aguilera, P., & Lopez-Contreras, A. J. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.02.009 · Cited by 122
5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy
Vasanthakumar, A., & Godley, L. A. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.02.009 · Cited by 116
Organ-Specific Cancer Metabolism and Its Potential for Therapy
Elia, I., Schmieder, R., Christen, S., & Fendt, S. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_10 · Cited by 112
López-Bertoni, H., Lal, B., Li, A., Caplan, M. J., Guerrero‐Cazares, H., Eberhart, C. G., Quiñones-Hinojosa, A., Glas, M., Scheffler, B., Laterra, J., et al. (2014) · Oncogene · doi:10.1038/onc.2014.334 · Cited by 113
Zhang, J., Liu, H., Tong, H., Wang, S., Yang, Y., Liu, G., & Zhang, W. (2017) · Contrast Media & Molecular Imaging · doi:10.1155/2017/7064120 · Cited by 111
Genotoxic therapy and resistance mechanism in gliomas
Lang, F., Liu, Y., Chou, F.-J., & Yang, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107922 · Cited by 116
Epigenetic therapy in gastrointestinal cancer: the right combination
Abdelfatah, E., Kerner, Z. J., Nanda, N., & Ahuja, N. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16644247 · Cited by 115
Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma
Goeppert, B. F., Tóth, R., Singer, S., Albrecht, T., Lipka, D. B., Lutsik, P., Brocks, D., Baehr, M., Muecke, O., Assenov, Y., et al. (2019) · Hepatology · doi:10.1002/hep.30493 · Cited by 112
Molecular mechanisms in colitis-associated colorectal cancer
Zhou, R. W., Harpaz, N., Itzkowitz, S. H., & Parsons, R. E. (2023) · Oncogenesis · doi:10.1038/s41389-023-00492-0 · Cited by 123
Comprehensive analysis of PD-L1 expression in glioblastoma multiforme
Heiland, D. H., Haaker, G., Delev, D., Mercas, B., Masalha, W., Heynckes, S., Gaebelein, A., Pfeifer, D., Carro, M. S., Weyerbrock, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15031 · Cited by 113
Glutamine‐fueled mitochondrial metabolism is decoupled from glycolysis in melanoma
Filipp, F. V., Ratnikov, B. I., Ingeniis, J. D., Smith, J. W., Osterman, A. L., & Scott, D. A. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12000 · Cited by 115
Ene, C., Edwards, L., Riddick, G., Baysan, M. S., Woolard, K., Kotliarova, S. E., Lai, C., Belova, G. I., Cam, M. C., Walling, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051407 · Cited by 115
Kaminska, B., Czapski, B., Guzik, R., Król, S. K., & Gielniewski, B. (2019) · Molecules · doi:10.3390/molecules24050968 · Cited by 113
Wang, Y., Wild, A. T., Turcan, Ş., Wu, W., Sigel, C., Klimstra, D. S., Ma, X., Gong, Y., Holland, E. C., Huse, J. T., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz3221 · Cited by 109
Self-citationRivadeneira, D. B., Caino, M. C., Seo, J. H., Angelin, A., Wallace, D. C., Languino, L. R., & Altieri, D. C. (2015) · Science Signaling · doi:10.1126/scisignal.aab1624 · Cited by 114
NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age
Gray, G. K., McFarland, B. C., Nozell, S. E., & Benveniste, E. N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.964211 · Cited by 109
Molenaar, R. J., Radivoyevitch, T., Nagata, Y., Khurshed, M., Przychodzen, B., Makishima, H., Xu, M., Bleeker, F. E., Wilmink, J. W., Carraway, H. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2796 · Cited by 112
Diagnostic, prognostic and predictive relevance of molecular markers in gliomas
Brandner, S., & von Deimling, A. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12246 · Cited by 108
Epigenomic Reprogramming as a Driver of Malignant Glioma
Phillips, R. E., Soshnev, A. A., & Allis, C. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.008 · Cited by 111
Suwala, A. K., Stichel, D., Schrimpf, D., Kloor, M., Wefers, A. K., Reinhardt, A., Maas, S. L. N., Kratz, C. P., Schweizer, L., Hasselblatt, M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02243-6 · Cited by 108
The Metabolic Alterations of Cancer Cells
Sciacovelli, M., Gaude, E., Hilvo, M., & Frezza, C. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-416618-9.00001-7 · Cited by 108
The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells
Smolková, K., & Ježek, P. (2012) · International Journal of Cell Biology · doi:10.1155/2012/273947 · Cited by 114
Li, L., Paz, A. C., Wilky, B. A., Johnson, B. A., Galoian, K. A., Rosenberg, A. E., Hu, G., Tinoco, G., Bodamer, O. A., & Trent, J. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133813 · Cited by 107
An epigenetic gateway to brain tumor cell identity
Mack, S. C., Hubert, C. G., Miller, T. E., Taylor, M. D., & Rich, J. N. (2015) · Nature Neuroscience · doi:10.1038/nn.4190 · Cited by 106
New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
Dimitrov, L., Hong, C. S., Yang, C., Zhuang, Z., & Heiss, J. D. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.11047 · Cited by 108
Epigenetic modifiers as new immunomodulatory therapies in solid tumours
Aspeslagh, S., Morel, D., Soria, J., & Postel-Vinay, S. C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy050 · Cited by 105
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis
Johannessen, T.-C. A., Mukherjee, J., Viswanath, P., Ohba, S., Ronen, S. M., Bjerkvig, R., & Pieper, R. O. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0141 · Cited by 105
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
Chen, R., Cohen, A. L., & Colman, H. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0418-0 · Cited by 104
Non‐canonical Bases in the Genome: The Regulatory Information Layer in DNA
Carell, T., Kurz, M. Q., Müller, M., Rossa, M., & Spada, F. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201708228 · Cited by 104
The role of aberrant DNA methylation in cancer initiation and clinical impacts
Geissler, F., Nesic, K., Kondrashova, O., Dobrovic, A., Swisher, E. M., Scott, C. L., & Wakefield, M. J. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231220511 · Cited by 112
DNA Methylation Data Analysis and its Application to Cancer Research
Ma, X., Wang, Y.-W., Zhang, M. Q., & Gazdar, A. F. (2013) · Epigenomics · doi:10.2217/epi.13.26 · Cited by 101
He, X., Yan, B., Liu, S., Jia, J., Lai, W., Xing, X., Tang, C., Luo, D., Tan, T., Jiang, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0268 · Cited by 105
Machine learning classifies cancer
Wong, D., & Yip, S. S. F. (2018) · Nature · doi:10.1038/d41586-018-02881-7 · Cited by 102
TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal Transition
Morin, A., Goncalves, J., Moog, S., Castro‐Vega, L. J., Job, S., Buffet, A., Fontenille, M., Woszczyk, J., Gimenez‐Roqueplo, A., Letouzé, É., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.022 · Cited by 110
Fukushima, S., Yamashita, S., Kobayashi, H., Takami, H., Fukuoka, K., Nakamura, T., Yamasaki, K., Matsushita, Y., Nakamura, H. K., Totoki, Y., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1673-2 · Cited by 101
Blockade of Glutathione Metabolism in IDH1 -Mutated Glioma
Tang, X., Fu, X., Liu, Y., Yu, D., Cai, S. J., & Yang, C. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0103 · Cited by 100
Tanboon, J., Williams, E. A., & Louis, D. N. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlv009 · Cited by 100
Epigenetic Regulation of the miR142-3p/Interleukin-6 Circuit in Glioblastoma
Chiou, G., Chien, C., Wang, M., Chen, M.-T., Yang, Y., Yu, Y., Chien, Y., Chang, Y., Shen, C., Chio, C., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.11.009 · Cited by 100
Understanding genomic alterations in cancer genomes using an integrative network approach
Wang, E. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.050 · Cited by 100
Glioblastoma: Molecular Analysis and Clinical Implications
Huse, J. T., Holland, E. C., & DeAngelis, L. M. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-100711-143028 · Cited by 96
Self-citationGallo, M., Coutinho, F. J., Vanner, R. J., Gayden, T., Mack, S. C., Murison, A., Remke, M., Ren, L., Takayama, N., Desai, K., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.005 · Cited by 97
Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcomaPreprint
Totoki, Y., Yoshida, A., Hosoda, F., Nakamura, H. K., Hama, N., Ogura, K., Yoshida, A., Fujiwara, T., Arai, Y., Toguchida, J., et al. (2014) · Genome Research · doi:10.1101/gr.160598.113 · Cited by 97
A glioma classification scheme based on coexpression modules of EGFR and PDGFRA
Sun, Y., Zhang, W., Chen, D., Lv, Y.-H., Zheng, J., Lilljebjörn, H., Liang, R., Bao, Z., Soneson, C., Sjögren, H. O., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313814111 · Cited by 96
Glutamine Metabolism in Brain Tumors
Natarajan, S. K., & Venneti, S. (2019) · Cancers · doi:10.3390/cancers11111628 · Cited by 99
Spyropoulou, A., Gargalionis, A. N., Dalagiorgou, G., Adamopoulos, C., Papavassiliou, K. A., Lea, R. W., Piperi, C., & Papavassiliou, A. G. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8254-x · Cited by 95
5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer
Kroeze, L. I., van der Reijden, B. A., & Jansen, J. H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.001 · Cited by 97
Biological significance of the CpG island methylator phenotype
Suzuki, H., Yamamoto, E., Maruyama, R., Niinuma, T., & Kai, M. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.007 · Cited by 99
Molenaar, R. J., Thota, S., Nagata, Y., Patel, B. J., Clemente, M. J., Przychodzen, B. P., Hirsch, C. M., Viny, A. D., Hosano, N., Bleeker, F. E., et al. (2015) · Leukemia · doi:10.1038/leu.2015.91 · Cited by 101
A basic review on systemic treatment options in WHO grade II-III gliomas
Mair, M. J., Geurts, M., van den Bent, M. J., & Berghoff, A. S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102124 · Cited by 99
Signaling pathways in brain tumors and therapeutic interventions
Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 105
Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma
Guan, X., Vengoechea, J. E., Zheng, S., Sloan, A. E., Chen, Y., Brat, D. J., O’Neill, B. P., de Groot, J., Yust‐Katz, S., Yung, W.-K. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091216 · Cited by 93
Wiestler, B., Claus, R., Hartlieb, S. A., Schliesser, M. G., Weiß, E. K., Hielscher, T., Platten, M., Dittmann, L. M., Meisner, C., Felsberg, J., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not043 · Cited by 93
Gupta, V. K., Sharma, N., Durden, B. C., Garrido, V. T., Kesh, K., Edwards, D., Wang, D., Myer, C., Mateo-Victoriano, B., Kollala, S. S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2562 · Cited by 97
DNA Damage, DNA Repair and Cancer
Bernstein, C., Anil, R., Nfonsam, V. N., & Bernstei, H. (2013) · InTech eBooks · doi:10.5772/53919 · Cited by 115
Microenvironmental Heterogeneity in Brain Malignancies
Perus, L. J. M., & Walsh, L. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02294 · Cited by 96
Self-citationShukla, S., Patric, I. R. P., Patil, V., Shwetha, S. D., Hegde, A. S., Chandramouli, B. A., Arivazhagan, A., Santosh, V., & Somasundaram, K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.567032 · Cited by 88
Precision medicine in pediatric oncology: Lessons learned and next steps
Mody, R. J., Prensner, J. R., Everett, J. N., Parsons, D. W., & Chinnaiyan, A. M. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26288 · Cited by 94
Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations
Zhou, S., Treloar, A. E., & Lupien, M. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0745 · Cited by 89
MELK expression correlates with tumor mitotic activity but is not required for cancer growth
Giuliano, C. J., Lin, A., Smith, J. C., Palladino, A. C., & Sheltzer, J. M. (2018) · eLife · doi:10.7554/elife.32838 · Cited by 95
Epigenetic regulators in cancer therapy and progression
Marei, H. E. S. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01003-7 · Cited by 116
Brain stem cells as the cell of origin in glioma
Modrek, A. S. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i1.43 · Cited by 90
Moving toward molecular classification of diffuse gliomas in adults
Theeler, B. J., Yung, W. K. A., Fuller, G. N., & de Groot, J. (2012) · Neurology · doi:10.1212/wnl.0b013e318271f7cb · Cited by 90
Remacha, L., Comino‐Méndez, I., Richter, S., Contreras, L., Currás-Freixes, M., Pita, G., Letón, R., Galarreta, A., Torres‐Pérez, R., Honrado, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2250 · Cited by 98
Libby, C. J., Tran, A. N., Scott, S. E., Griguer, C. E., & Hjelmeland, A. B. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.01.004 · Cited by 91
Targeting IDH1-Mutated Malignancies with NRF2 Blockade
Liu, Y., Lu, Y., Celiku, O., Li, A., Wu, Q., Zhou, Y., & Yang, C. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy230 · Cited by 91
Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas
Remacha, L., Pirman, D. A., Mahoney, C. E., Coloma, J., Calsina, B., Currás-Freixes, M., Letón, R., Torres‐Pérez, R., Richter, S., Pita, G., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.017 · Cited by 88
The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas
Gargini, R., Segura‐Collar, B., Herránz, B., García‐Escudero, V., Romero-Bravo, A., Núñez, F. J., García‐Pérez, D., Gutiérrez-Guamán, J., Ayuso‐Sacido, Á., Seoane, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax1501 · Cited by 89
Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
Alzial, G., Renoult, O., Paris, F., Gratas, C., Clavreul, A., & Pecqueur, C. (2021) · Oncogene · doi:10.1038/s41388-021-02056-1 · Cited by 101
Pusch, S., Schweizer, L., Beck, A.-C., Lehmler, J.-M., Weißert, S., Balß, J., Miller, A. K., & von Deimling, A. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-19 · Cited by 93
The Evolving Molecular Genetics of Low-grade Glioma
Venneti, S., & Huse, J. T. (2015) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000049 · Cited by 90
Self-citationFontebasso, A. M., Liu, X., Sturm, D., & Jabado, N. (2013) · Brain Pathology · doi:10.1111/bpa.12023 · Cited by 89
Wiestler, B., Capper, D., Hovestadt, V., Sill, M., Jones, D., Hartmann, C. J., Felsberg, J., Platten, M., Feiden, W., Keyvani, K., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou138 · Cited by 88
Nguyen, D. N., Heaphy, C. M., de Wilde, R. F., Orr, B. A., Odia, Y., Eberhart, C. G., Meeker, A. K., & Rodríguez, F. J. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00630.x · Cited by 92
Mancarella, D., & Plass, C. (2021) · Genome Medicine · doi:10.1186/s13073-021-00837-7 · Cited by 91
Danussi, C., Bose, P., Parthasarathy, P. T., Silberman, P. C., Arnam, J. S. V., Vitucci, M., Tang, O. Y., Heguy, A., Wang, Y., Chan, T. A.-T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03476-6 · Cited by 91
Self-citationD-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in micePreprint
Akbay, E. A., Moslehi, J. J., Christensen, C. L., Saha, S. K., Tchaicha, J. H., Ramkissoon, S. H., Stewart, K. M., Carretero, J., Kikuchi, E., Zhang, H., et al. (2014) · Genes & Development · doi:10.1101/gad.231233.113 · Cited by 93
Hyperpolarized [1-13C] Glutamate: A Metabolic Imaging Biomarker of IDH1 Mutational Status in Glioma
Chaumeil, M. M., Larson, P. E. Z., Woods, S. M., Cai, L., Eriksson, P., Robinson, A. E., Lupo, J., Vigneron, D. B., Nelson, S. J., Pieper, R. O., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0680 · Cited by 87
Rare insights into cancer biology
Adam, J., Yang, M., Soga, T., & Pollard, P. J. (2013) · Oncogene · doi:10.1038/onc.2013.222 · Cited by 90
Advances in Research of Adult Gliomas
Finch, A., Solomou, G., Wykes, V., Pohl, U., Bardella, C., & Watts, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020924 · Cited by 91
Transcriptional diversity of long-term glioblastoma survivors
Gerber, N. K., Goenka, A., Turcan, Ş., Reyngold, M., Makarov, V., Kannan, K. S., Beal, K. P., Omuro, A. M. P., Yamada, Y. J., Gutin, P. H., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou043 · Cited by 88
Self-citationReaders of DNA methylation, the MBD family as potential therapeutic targets
Ginder, G. D., & Williams, D. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.002 · Cited by 92
Metadata
- Authors
- Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., Thompson, C. B., Kaufman, A., Guryanova, O., Levine, R., Heguy, A., Viale, A., Morris, L. G. T., Huse, J. T., Mellinghoff, I. K., & Chan, T. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Mellinghoff, Ingo K.
- Chan, Timothy A.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 479-483
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3351699
- OpenAlex
- W1988756388
- Cited by
- 1,974
- References
- 44
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 100 · 2022: 136 · 2021: 148 · 2020: 140 · 2019: 142 · 2018: 169 · 2017: 144 · 2016: 163 · 2015: 154 · 2014: 153 · 2013: 152 · 2012: 83
- FWCI
- 82.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (F31CA260794, R01CA154767, U54CA143798, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, glioma, CpG island methylator phenotype, DNA hypermethylation, 2-hydroxyglutarate, oncometabolites, histone demethylation, methylome, astrocytes, gliomagenesis, hypoxia-inducible factor, epigenetic reprogramming
- MeSH terms
- Astrocytes, Cell Survival, Cells, Cultured, Gene Expression Regulation, Glioblastoma, Glioma, Histones, Humans, Isocitrate Dehydrogenase, Mutation, Phenotype, Tumor Cells, Cultured, CpG Islands, DNA Methylation, Epigenesis, Genetic, Metabolome, HEK293 Cells, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
